Does China not move to the beat of their own drum? If the endpoint isn’t met in the BOM trial, but the sub groups do well and our safety rating holds strong, can China not start dosing their citizens with 208 and generate some income for RVX that can be used to finance new trials for those indications that, if become successful, would some day satisfy the FDA? 

DND